| 摘要: |
| 目的 检测DLEC1 (deleted in lung and esophageal cancer 1) 基因在结直肠癌 (colorectal cancer, CRC) 患者组织和血清中的甲基化状态,分析其临床意义。方法 留取71例CRC患者癌组织、相应正常组织及术前血清标本,20例肠道良性病变及20例健康志愿者血清标本,甲基化特异性聚合酶链反应(MSP)检测DLEC1基因启动子区域甲基化情况。结果 71例CRC组织中,DLEC1基因启动子甲基化比例为45.1%(32/71),而正常组织为7.1%(4/56),差异有统计学意义(P<0.001);DLEC1基因启动子甲基化与患者临床病理特征及CEA、CA19-9水平之间无相关性。相应CRC血清DNA中DLEC1甲基化比例为39.4%(28/71),而对照组为2.5%(1/40)，差异有统计学意义(P<0.001),且血清DNA甲基化状况与组织中具有良好的一致性。结论 DLEC1基因启动子甲基化在CRC患者中有着较高的检出率,可望成为CRC辅助诊断的新型分子标记。 |
| 关键词: 结直肠肿瘤 DLEC1 DNA甲基化 生物学标记 |
| DOI：10.3724/SP.J.1008.2010.0842 |
| 投稿时间：2009-11-28修订日期：2010-07-06 |
| 基金项目: |
|
| Methylation status of DLEC1 promoter in colorectal cancer patients and its clinical relevance |
| YE Xiao-bing1, ZHANG You-wei2,,Long-bang2* |
| (1. Postgraduate Class, Medical College, Nanjing University, Naniing 210008, Jiangsu, China;2.Department of Medical Oncology, Jinling Hospital (General Hospital, PLA Nanjing Military Area Command), Medical School of Nanjing University, Nanjing 210002, Jiangsu, China) |
| Abstract: |
| Objective To detect the methylation status of DLEC1 promoter in the tissue and serum of colorectal cancer (CRC) patients and to evaluate its clinical relevance. Methods Genomic DNA was extracted from the tissues (cancer tissue and corresponding adjacent normal tissue) and sera of 71 CRC patients; serum genomic DNA was also obtained from 20 patients with benign gastrointestinal diseases and 20 healthy donors. Promoter methylation status of DLEC1 gene was detected by methylation-specific polymerase chain reaction (MSP). Results The incidence of aberrant methylation of DLEC1 promoter was 45.1% (32/71) in CRC tissues, which was significantly higher than that in the adjacent normal tissues (7.1%,4/56) (P<0.001). The hypermethylation status of DLEC1 was not correlated with the clinicopathological features and CEA/CA19-9 levels of CRC patients. Moreover, DLEC1 promoter methylation was also found in 28 of 71 (39.4%) CRC serum samples and only 1 (2.5%) of the other 40 cancer-free serum samples (P<0.001); the methylation was in accordance with that in the tumor tissues. Conclusion Hypermethylation of DLEC1 promoter is frequently seen in CRC patients, suggesting it might be a promising biomarker for the early diagnosis of CRC. |
| Key words: colorectal neoplasms DLEC1 DNA methylation biological markers |
